Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Neoadjuvant Dose Dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

NCT01611662 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT01611662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01611662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Neoadjuvant Dose Dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
May 29, 2012
Completion date
January 22, 2019
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

distal urethral cancer, proximal urethral cancer, squamous cell carcinoma of the bladder, stage ii bladder cancer, stage iii bladder cancer, urethral cancer associated with invasive bladder cancer